Cancer is the 2nd major cause of human morbidity and mortality. Consequently, PhD and MD/PhD researchers trained in Cancer Biology and professionally involved in cancer research are a critical national health need. It is our view that a truly interdisciplinary graduate curriculum with a major focus upon the biology of cancer that interfaces with clinicians engaged in cancer diagnosis and treatment provides an excellent means of training specialists with a sufficient breadth of perspective for a successful independent career in cancer research. This is an application for renewal of a training grant currently in its 20th year to support 6 pre-doctoral candidates principally from the Graduate Program in Cancer Biology (GPCB) at the Wayne State University (WSU) and the Karmanos Cancer Institute (KCI). Trainees will include both PhD and MD/PhD candidates and are selected from our diverse candidate population, including underrepresented minorities. Training draws from the outstanding clinical and research facilities at WSU/KCI and the expertise of 17 training faculty in areas ranging from fundamental processes involved in neoplastic development, invasion and metastasis, to cancer therapy and prevention. A cornerstone of our training environment is the GPCB, comprised of over 50 faculty from academic and clinical departments throughout our university, that provides a unique educational environment through extended cancer courses, lectures, seminars and symposia that culminates in a PhD in Cancer Biology. Graduate students will have the opportunity to become familiar with state-of-the-art methods in molecular and cell biology and will receive clinical exposure to the cancer problem through """"""""rounding"""""""" with oncologists at the KCI Cancer Hospital and attendance at KCI Grand Rounds. Training of the most outstanding graduate candidates from the GPCB will be significantly enhanced by a 2 year appointment to this NCI-sponsored training grant. The training experience for the T32 trainees will enable each to pursue a successful career in cancer research. During the past 20 years, this T32 CA009351 grant has trained an impressive group of cancer biologists who are currently contributing to basic scientific and translational cancer research efforts at research institutes throughout the United States. In accomplishing this, the training program has significantly contributed to meeting the critical national need for domestic and US-trained PhDs with a long term career commitment to cancer related research.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Institutional National Research Service Award (T32)
Project #
5T32CA009531-25
Application #
8134751
Study Section
Special Emphasis Panel (ZCA1-RTRB-A (M1))
Program Officer
Damico, Mark W
Project Start
1985-09-01
Project End
2012-08-31
Budget Start
2011-09-01
Budget End
2012-08-31
Support Year
25
Fiscal Year
2011
Total Cost
$138,843
Indirect Cost
Name
Wayne State University
Department
Pharmacology
Type
Schools of Medicine
DUNS #
001962224
City
Detroit
State
MI
Country
United States
Zip Code
48202
Murray, Andrew S; Varela, Fausto A; Hyland, Thomas E et al. (2017) Phosphorylation of the type II transmembrane serine protease, TMPRSS13, in hepatocyte growth factor activator inhibitor-1 and -2-mediated cell-surface localization. J Biol Chem 292:14867-14884
Blocker, Stephanie J; Douglas, Kirk A; Polin, Lisa Anne et al. (2017) Liposomal 64Cu-PET Imaging of Anti-VEGF Drug Effects on Liposomal Delivery to Colon Cancer Xenografts. Theranostics 7:4229-4239
Chatterjee, Madhumita; Hurley, Laura C; Tainsky, Michael A (2017) Paraneoplastic antigens as biomarkers for early diagnosis of ovarian cancer. Gynecol Oncol Rep 21:37-44
Watza, Donovan; Purrington, Kristen S; Chen, Kang et al. (2017) Transcriptional programs of tumor infiltrating T-cells provide insight into mechanisms of immune response and new targets for immunotherapy. J Thorac Dis 9:4162-4164
Sanders, Matthew A; Haynes, Brittany; Nangia-Makker, Pratima et al. (2017) Pharmacological targeting of RAD6 enzyme-mediated translesion synthesis overcomes resistance to platinum-based drugs. J Biol Chem 292:10347-10363
Jones, Steven K; Sarkar, Anwesha; Feldmann, Daniel P et al. (2017) Revisiting the value of competition assays in folate receptor-mediated drug delivery. Biomaterials 138:35-45
Haynes, Brittany; Sarma, Ashapurna; Nangia-Makker, Pratima et al. (2017) Breast cancer complexity: implications of intratumoral heterogeneity in clinical management. Cancer Metastasis Rev 36:547-555
Jones, Steven K; Lizzio, Vincent; Merkel, Olivia M (2016) Folate Receptor Targeted Delivery of siRNA and Paclitaxel to Ovarian Cancer Cells via Folate Conjugated Triblock Copolymer to Overcome TLR4 Driven Chemotherapy Resistance. Biomacromolecules 17:76-87
Najor, Nicole A; Weatherford, Layne; Brush, George S (2016) Prevention of DNA Rereplication Through a Meiotic Recombination Checkpoint Response. G3 (Bethesda) 6:3869-3881
Haynes, Brittany; Zhang, Yanhua; Liu, Fangchao et al. (2016) Gold nanoparticle conjugated Rad6 inhibitor induces cell death in triple negative breast cancer cells by inducing mitochondrial dysfunction and PARP-1 hyperactivation: Synthesis and characterization. Nanomedicine 12:745-757

Showing the most recent 10 out of 143 publications